At a glance
- Originator Merck & Co
- Class Triterpenes
- Mechanism of Action Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 10 Feb 2000 New profile
- 10 Feb 2000 Preclinical development for Mycoses in USA (Unknown route)